June 22, 2020 / 11:29 AM / 19 days ago

BRIEF-Merck’s Keytruda Approved In China For Esophageal Squamous Cell Carcinoma

June 22 (Reuters) - Merck & Co Inc:

* MERCK’S KEYTRUDA (PEMBROLIZUMAB) APPROVED IN CHINA FOR SECOND-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE TUMORS EXPRESS PD-L1 (CPS ≥10)

* MERCK - KEYTRUDA IS NOW APPROVED ACROSS FIVE INDICATIONS FOR THREE DIFFERENT TYPES OF CANCER IN CHINA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below